Amicogen 2026 Q1: Revenue up, operating loss narrows, net profit swings to black on one-time gains
Consolidated sales 122.8 billion won (+13.5% YoY), operating loss 31.7 billion won (improved from -43.3 billion)
Net profit 193.7 billion won (vs loss in prior year quarter), driven by one-time gains: subsidiary investment gain 20.2 billion won and equity method gains 5.0 billion won
Completed paid-in capital increase in Feb 2026, raising 17.2 billion won (14,925,374 shares)
R&D expenses 14.1 billion won (11.45% of sales)
Two ongoing lawsuits deemed immaterial. Contingent liabilities: guarantee for Puriogen's RCPS 31.8 billion won, joint guarantee 1.45 billion won